RecruitingPhase 3NCT06833983

To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A

Studying Hemophilia

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Gritgen Therapeutics Co., Ltd.
Intervention: GS1191-0445 injection(drug)
Enrollment: 50 enrolled
Eligibility: 18-65 years · MALE
Timeline: 2025 – 2030

Study locations (13)

Anhui Provincial Hospital, Hefei, Anhui, China
Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
First Hospital of Lanzhou University, Lanzhou, Gansu, China
Nanfang Hospital Southern Medical University, Guangzhou, Guangdong, China
North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Xiangya Hospital of Central South University, Changsha, Hunan, China
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
Jiangxi Provincial People's Hospital, Nanchang, Jiangxi, China
Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin Municipality, China
The second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06833983 on ClinicalTrials.gov

Other trials for Hemophilia

Additional recruiting or active studies for the same condition.

See all trials for Hemophilia →

← Back to all trials